肾功能不全的心脏再移植受者从同期心肾联合移植中获益
基于美国器官共享联合网络2005至2020年1189例成人心脏再移植患者,比较同期肾移植(HRT-KT,n=251)与单纯心脏再移植(HRT,n=938)。HRT-KT组5年生存率80.5% vs HRT组69.1%(p<0.001)。校正后,eGFR<30及30-45 ml/min/1.73m2组HRT-KT与5年生存改善相关,eGFR>45 ml/min/1.73m2组无统计学显著获益。
要点
- 心脏再移植合并肾功能不全eGFR<45 ml/min/1.73m2者,同期肾移植与5年生存改善相关。
- eGFR<30 ml/min/1.73m2组校正后HR 0.42(95%CI 0.26-0.67)。
- eGFR 30-45 ml/min/1.73m2组校正后HR 0.29(95%CI 0.13-0.65)。
核心结论
- 对于eGFR<45 ml/min/1.73m2的心脏再移植患者,同期肾移植与生存改善相关,应强烈考虑以优化器官分配管理。
研究设计与样本
- 基于美国器官共享联合网络数据库的回顾性队列研究,纳入2005至2020年1189例成人心脏再移植患者,HRT-KT组251例,HRT组938例。
主要发现
- HRT-KT组较HRT组年龄更大、等待时间更长、两次移植间隔更长、eGFR更低。
- HRT-KT组术前需要呼吸机支持的比例为1.2% vs HRT组9.0%(p<0.001),需要ECMO支持的比例为2.0% vs 8.3%(p<0.001)。
- HRT-KT组严重功能受限比例为63.4% vs HRT组52.6%(p=0.001)。
- 再移植后HRT-KT组治疗性急性排斥反应比例为5.2% vs HRT组9.3%(p=0.02),出院前需要透析的比例为29.1% vs 20.2%(p<0.001)。
- 5年生存率HRT-KT组为80.5% vs HRT组69.1%(p<0.001)。
关键数值与推荐
- 校正后,eGFR<30 ml/min/1.73m2组HRT-KT的5年生存HR为0.42(95%CI 0.26-0.67)。
- 校正后,eGFR 30-45 ml/min/1.73m2组HRT-KT的5年生存HR为0.29(95%CI 0.13-0.65)。
- 校正后,eGFR>45 ml/min/1.73m2组HRT-KT的5年生存HR为0.68(95%CI 0.30-1.54),未达统计学显著。
临床怎么用
- 作者结论认为,对eGFR<45 ml/min/1.73m2的心脏再移植患者,同期肾移植与生存改善相关,应强烈考虑以优化器官分配管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given ongoing donor shortages, appropriate patient selection for dual-organ transplantation is critical. We evaluated outcomes of heart retransplant with simultaneous kidney transplant (HRT-KT) vs isolated heart retransplant (HRT) across varying levels of renal dysfunction. METHODS: The United Network for Organ Sharing database identified 1189 adult patients undergoing heart retransplantation between 2005 and 2020. Recipients undergoing HRT-KT (n = 251) were compared to those undergoing HRT (n = 938). The primary outcome was 5-year survival; subgroup analyses and multivariable adjustment were performed utilizing the following 3 estimated glomerular filtration (eGFR) groups: <30 ml/min/1.73m2, 30-45 ml/min/1.73m2, and >45 ml/min/1.73m2. RESULTS: HRT-KT recipients were older and had longer waitlist times, longer inter-transplant periods, and lower eGFR levels. HRT-KT recipients were less likely to require pretransplant ventilator (1.2% vs 9.0%, p < 0.001) or ECMO (2.0% vs 8.3%, p < 0.001) support but were more likely to have severe functional limitation (63.4% vs 52.6%, p = 0.001). After retransplantation, HRT-KT recipients had less treated acute rejection (5.2% vs 9.3%, p = 0.02) and more dialysis requirement (29.1% vs 20.2%, p < 0.001) before discharge. Survival at 5-years was 69.1% after HRT and 80.5% after HRT-KT (p < 0.001). After adjustment, HRT-KT was associated with improved 5-year survival among recipients with eGFR <30 ml/min/1.73m2 (HR:0.42, 95% CI: 0.26-0.67) and 30 to 45 ml/min/1.73m2 (HR:0.29, 95% CI 0.13-0.65), but not among those with eGFR>45 ml/min/1.73sm2 (HR 0.68, 95% CI 0.30-1.54). CONCLUSION: Simultaneous kidney transplantation is associated with improved survival following heart retransplantation in patients with eGFR <45 ml/min/1.73m2 and should be strongly considered to optimize organ allocation stewardship.
引用
- Malas J, Chen Q, Emerson D, et al. Heart retransplant recipients with renal dysfunction benefit from simultaneous heart-kidney transplantation. J Heart Lung Transplant. 2023. PMID: 37098375. doi:10.1016/j.healun.2023.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。